These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28412383)

  • 1. A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study.
    Risslegger B; Zoran T; Lackner M; Aigner M; Sánchez-Reus F; Rezusta A; Chowdhary A; Taj-Aldeen SJ; Arendrup MC; Oliveri S; Kontoyiannis DP; Alastruey-Izquierdo A; Lagrou K; Lo Cascio G; Meis JF; Buzina W; Farina C; Drogari-Apiranthitou M; Grancini A; Tortorano AM; Willinger B; Hamprecht A; Johnson E; Klingspor L; Arsic-Arsenijevic V; Cornely OA; Meletiadis J; Prammer W; Tullio V; Vehreschild JJ; Trovato L; Lewis RE; Segal E; Rath PM; Hamal P; Rodriguez-Iglesias M; Roilides E; Arikan-Akdagli S; Chakrabarti A; Colombo AL; Fernández MS; Martin-Gomez MT; Badali H; Petrikkos G; Klimko N; Heimann SM; Houbraken J; Uzun O; Edlinger M; Fuente S; Lass-Flörl C
    Clin Microbiol Infect; 2017 Oct; 23(10):776.e1-776.e5. PubMed ID: 28412383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B.
    Escribano P; Peláez T; Recio S; Bouza E; Guinea J
    Clin Microbiol Infect; 2012 Feb; 18(2):E24-6. PubMed ID: 22128886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex.
    Vaezi A; Fakhim H; Arastehfar A; Shokohi T; Hedayati MT; Khodavaisy S; Rezaei-Matehkolaei A; Badiee P; Hagen F; Lass-Flörl C; Dannaoui E; Meis JF; Badali H
    Mycoses; 2018 Feb; 61(2):134-142. PubMed ID: 29064123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.
    Sutton DA; Sanche SE; Revankar SG; Fothergill AW; Rinaldi MG
    J Clin Microbiol; 1999 Jul; 37(7):2343-5. PubMed ID: 10364610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective survey of Aspergillus spp. in respiratory tract samples: Species identification and susceptibility patterns.
    Castro C; Galán-Sanchez F; Linares MJ; Tejero R; Ruiz M; Serrano ML; Rodríguez-Iglesias M; Martín-Mazuelos E;
    Med Mycol; 2019 Jun; 57(4):412-420. PubMed ID: 30289467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study.
    Rüping MJ; Gerlach S; Fischer G; Lass-Flörl C; Hellmich M; Vehreschild JJ; Cornely OA
    J Hosp Infect; 2011 Jul; 78(3):226-30. PubMed ID: 21440331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
    Misra R; Malik A; Singhal S
    Indian J Pathol Microbiol; 2011; 54(1):112-6. PubMed ID: 21393890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies.
    Colozza C; Posteraro B; Santilli S; De Carolis E; Sanguinetti M; Girmenia C
    Int J Antimicrob Agents; 2012 May; 39(5):440-3. PubMed ID: 22429723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
    Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
    J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
    Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
    J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential basis for amphotericin B resistance in Aspergillus terreus.
    Blum G; Perkhofer S; Haas H; Schrettl M; Würzner R; Dierich MP; Lass-Flörl C
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1553-5. PubMed ID: 18268082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillusnidulans complex and Aspergillusterreus complex isolated from clinical specimens.
    Mohamadnia A; Salehi Z; Namvar Z; Tabarsi P; Pourabdollah-Toutkaboni M; Rezaie S; Marjani M; Moniri A; Abtahian Z; Mahdaviani SA; Mortezaee V; Askari E; Sharifynia S
    J Mycol Med; 2020 Sep; 30(3):101004. PubMed ID: 32534826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.
    Salas V; Pastor FJ; Sutton DA; Calvo E; Mayayo E; Fothergill AW; Rinaldi MG; Guarro J
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1532-4. PubMed ID: 23295929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp.
    Martín-Mazuelos E; Pemán J; Valverde A; Chaves M; Serrano MC; Cantón E
    J Antimicrob Chemother; 2003 Sep; 52(3):365-70. PubMed ID: 12917236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Aspergillus terreus at a university hospital.
    Baddley JW; Pappas PG; Smith AC; Moser SA
    J Clin Microbiol; 2003 Dec; 41(12):5525-9. PubMed ID: 14662934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular epidemiology and in-vitro antifungal susceptibility of Aspergillus terreus species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typing.
    Kathuria S; Sharma C; Singh PK; Agarwal P; Agarwal K; Hagen F; Meis JF; Chowdhary A
    PLoS One; 2015; 10(3):e0118997. PubMed ID: 25781896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luliconazole, an alternative antifungal agent against Aspergillus terreus.
    Zargaran M; Taghipour S; Kiasat N; Aboualigalehdari E; Rezaei-Matehkolaei A; Zarei Mahmoudabadi A; Shamsizadeh F
    J Mycol Med; 2017 Sep; 27(3):351-356. PubMed ID: 28483449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
    Warn PA; Morrissey G; Morrissey J; Denning DW
    J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspergillus terreus complex.
    Balajee SA
    Med Mycol; 2009; 47 Suppl 1():S42-6. PubMed ID: 19291598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.